MCL1 and B-cell chronic lymphocytic leukemia: These data suggest that knowledge of the post-translational modifications leading to increased or decreased half-life of the Mcl-1 protein in B cells may lead to important therapeutic applications in CLL, as well as in other forms of cancer.